Market Signal Briefing

Michael Saylor, executive chairman of Strategy (formerly MicroStrategy), has once again teased a potential Bitcoin acquisition through a cryptic post on X, writing "Stretch the Orange Dots" — a phrase followers have come to associate with upcoming BTC purchases. This marks the eleventh such hint Saylor has shared in 2026, continuing a pattern where Sunday posts typically precede formal Monday announcements.

The hint arrives just days after Strategy acquired 17,994 BTC last week, adding to what has become one of the largest corporate Bitcoin treasuries in existence. The company now holds 738,731 BTC across 102 purchases since late 2020, with a total cost basis of approximately $56.04 billion and an average entry price of around $75,863 per coin. At Bitcoin's current trading price of $71,300 — up 1.15% in the past 24 hours — the position reflects an unrealized loss of roughly $3 billion, or about 5.4%.

Despite ongoing price volatility, Strategy has shown no signs of slowing its accumulation strategy. The company continues to fund Bitcoin purchases through debt and equity financing, including an at-the-market share program that allows it to raise capital by selling stock. Crypto traders speculate the firm may have already added over 1,000 BTC this week based on activity linked to that program.

Investor interest in Strategy-related securities remains strong. The company's STRC preferred stock has emerged as the most liquid preferred instrument offering indirect Bitcoin exposure, drawing increasing demand from institutional and retail investors alike. MSTR shares traded at $138.40 in after-hours activity following a Friday close of $137.34, though short interest has also been rising, signaling some bearish positioning around the stock.

On-chain data adds broader context, with long-term Bitcoin holders currently controlling around 79% of circulating supply — a more stable distribution compared to the sharp decline seen during the 2021 market cycle.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Robert Kiyosaki warns a “giant crash” is accelerating as Warren Buffett piles up cash for turmoil, while he urgently shifts millions into bitcoin, gold, silver, and oil in preparation for what he believes could be the biggest market collapse in history.

Bitcoin has reclaimed the $72,000 price level, but seasoned traders are urging caution. Despite the psychological significance of breaching this key resistance zone, the current breakout is missing two critical ingredients: volume and volatility. Without these, the move may be more of a technical drift than a genuine bullish breakout.

After a sharp correction that pushed Bitcoin prices into the mid-$60,000 range earlier this year, BTC has been consolidating sideways around the $72,000 mark. The recovery has been technically structured, with a rising support base forming following February's sell-off. Bitcoin is now testing its 26-day exponential moving average from below, a short-term indicator closely watched by technical traders. However, the broader technical picture remains fragile.

Historically, when Bitcoin breaks above major psychological price levels, it is accompanied by a surge in trading volume and heightened market volatility. These signals confirm that new capital is entering the market and that traders are actively participating in the move. Neither of those conditions is present right now. Instead, Bitcoin appears to be floating higher on thin trading activity, a pattern that often precedes a swift reversal.

Another red flag is the weakness spreading across the altcoin market. In a true Bitcoin breakout scenario, strength typically spills over into other cryptocurrencies. Currently, most altcoins remain suppressed below key resistance levels, signaling that broader market sentiment is not aligned with BTC's upward push. This divergence further supports the idea that the move lacks conviction.

For the rally to be taken seriously, Bitcoin needs a measurable increase in both trading volume and volatility. Until those conditions are met, investors should approach the $72,000 breakout with careful skepticism, as low-volume moves in crypto have historically struggled to sustain upward momentum.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Decentralized finance protocol Aave said it is introducing a new feature to block swaps with a price impact above 25% after a user lost $50 million in a trade while interacting with Aave’s interface last week. 

“We are soon deploying a new feature, Aave Shield, which provides more protections for users who use the swap feature in the Aave interface aave.com,” Aave said in a post-mortem statement on Saturday.

Aave said users would need to manually disable the Aave Shield protection feature to proceed with high-risk trades.

The incident occurred on Thursday, when the user went to convert $50.4 million worth of USDt (USDT) for Aave (AAVE) via decentralized exchange CoW Swap, but received only $36,500 worth of Aave due to a lack of liquidity and other infrastructure failures, generating a loss of just over $50 million. 

Part of this loss was also a result of a Maximal Extractable Value (MEV) bot that executed a sandwich attack on the user, profiting nearly $10 million.

User ignored multiple warning signsAave said the user signed the transaction despite multiple warnings appearing on the platform’s interface. 

This included alerts about a “high price impact” and a notice stating the route might return less due to low liquidity or small order size. 

The user also ticked a confirmation box stating, “I confirm the swap with a potential 100% value loss,” Aave said. 

What the user would have seen on Aave’s interface before signing the transaction. Source: Aave
Incident shows DeFi still needs work: CoW DAO While Aave and CoW DAO, the team behind CoW Swap, said poor liquidity led to the “extreme price impact,” CoW DAO added that multiple infrastructure failures also played a role.

CoW DAO said a solver — a third-party service that finds the best way to do a trade — was affected by an outdated gas limit, which blocked better-priced quotes and left only a much worse option for the user to consider.

One solver, which had a far cheaper price quote, also failed to submit the transaction onchain when they had the opportunity, CoW DAO noted.

CoW DAO said a possible mempool leak may have contributed to the $50 million price quote.

“We do not have final answers on all of the issues surfaced above yet,” CoW DAO said, adding that it is “committed to working through them transparently, with Aave and with the broader community.”

Magazine: What’s a ‘Network State’ and are there real-life examples? Big Questions

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

📊
No votes yet – Be the first to vote

Crypto’s getting messy again.

Martin Köppelmann from Gnosis went hard against the CLARITY Act today, saying it’s basically trying to force all crypto stuff through US-licensed middlemen. The Gnosis co-founder thinks Congress wants to kill what makes crypto special – you know, the whole point of cutting out traditional finance gatekeepers. He’s pretty vocal about how the bill contradicts everything decentralized finance stands for, and honestly, he’s got a point when you look at what Gnosis actually does.

The Clarity for Digital Tokens Act sits in Congress right now, waiting for lawmakers to hash out the details. Supporters keep pushing the “investor protection” angle, claiming everyone needs legal certainty to feel safe putting money into digital assets. But critics like Köppelmann see it differently – they think it’ll crush innovation and basically hand control back to the same old financial institutions that crypto was supposed to replace. The whole debate feels like watching two different movies about the same story.

Gnosis runs prediction markets without banks. That’s the whole business model.

Founded back in 2015, Gnosis built its platform specifically to avoid traditional financial middlemen – users bet on outcomes directly with each other. Köppelmann worries the CLARITY Act would force transactions through licensed entities, which would pretty much destroy what makes his platform work. It’s not just about compliance costs, though those are brutal for smaller operations. The real issue is philosophical – requiring licensed intermediaries kills the peer-to-peer nature that defines decentralized finance.

Other blockchain startups share Köppelmann’s concerns, and they’re not staying quiet about it. Many fear the act favors big financial institutions that can easily absorb compliance costs and navigate licensing requirements. Smaller, newer projects don’t have those resources, so they’d either shut down or get bought out by larger players. That’s exactly the kind of market consolidation that crypto was supposed to prevent, but here we are talking about it anyway.

Representative Mark Warner keeps defending the bill during hearings. “Investors need protection,” he said recently, pushing back against industry criticism. Warner and other lawmakers think regulation prevents fraud and stabilizes markets, which sounds reasonable until you consider what that actually means for decentralized platforms. The crypto community generally hates government intervention, preferring to let market forces and code handle security and disputes.

Congress approaches a vote soon. Things get tense.

The debate’s heating up as lawmakers prepare to vote on the bill. Advocates highlight security benefits and consumer protections, while opponents focus on innovation risks and regulatory overreach. Nobody knows if the act will pass as written or face major amendments to address industry concerns. The uncertainty makes planning difficult for crypto companies trying to figure out their next moves. Market participants tracking CLARITY Act Hits Roadblocks as Stablecoin will find additional context here.

Right now, the act’s future remains unclear, and that’s probably intentional. Crypto industry leaders keep lobbying against passage, hoping to preserve decentralized operations without traditional financial oversight. Meanwhile, banks and licensed financial institutions wait quietly, knowing they’d benefit from increased control over digital asset transactions. It’s a classic regulatory capture scenario playing out in real time.

Köppelmann warns crypto projects might flee to friendlier jurisdictions if the act passes. That worries US policymakers who want America leading digital asset innovation, not watching it happen elsewhere. Countries like Switzerland, Singapore, and Portugal already attract crypto businesses with clearer, more flexible regulatory frameworks. A US exodus would hurt American technological leadership and tax revenue from a growing industry.

The act could hit small startups hardest while letting big players adapt more easily. Larger entities have legal teams and compliance budgets to handle new requirements, but smaller startups often operate on thin margins with minimal overhead. That disparity raises questions about whether the legislation accidentally creates barriers to entry that benefit established players over innovative newcomers.

Major crypto exchanges haven’t commented publicly yet. Their silence seems weird given their central role in the market ecosystem and the direct impact licensing requirements would have on their operations. Maybe they’re waiting to see which way the political winds blow before taking positions, or maybe they’re lobbying behind closed doors instead of making public statements.

The Securities and Exchange Commission watches closely as debates continue. Chair Gary Gensler commented last week about needing “robust safeguards” in digital assets, emphasizing consumer protection over innovation concerns. Gensler’s statements add complexity to ongoing discussions, since the SEC would likely enforce whatever rules Congress creates.

The Blockchain Association submitted a formal objection letter to Congress on March 10. Over 20 industry leaders signed the document, stressing potential negative impacts on smaller decentralized projects lacking compliance resources. The association wants a “balanced approach” that supports innovation while ensuring security, though they didn’t specify what that would look like in practice. This echoes themes explored in Buterin Wants Simpler Ethereum Nodes, underscoring the shifting landscape.

International regulators watch the US process with interest. The European Securities and Markets Authority noted the outcome could influence regulatory approaches globally, particularly regarding innovation versus oversight balance. That makes sense – if the US cracks down hard on crypto, other countries might follow suit or go the opposite direction to attract displaced businesses.

Tech entrepreneurs prepare contingency plans just in case. Jack Dorsey from Block Inc. hinted at potential strategic shifts during a March 12 conference call, mentioning exploration of alternative jurisdictions for operations. The global nature of crypto makes it easier for companies to relocate compared to traditional businesses tied to physical infrastructure.

Binance CEO Changpeng Zhao expressed concerns during a March 13 virtual panel. He argued stringent licensing requirements could drive innovation away from America, pointing out that blockchain projects thrive in flexible regulatory environments encouraging experimentation and growth. Zhao’s comments carry weight given Binance’s massive global market share.

Coinbase issued a statement March 14 emphasizing regulatory clarity importance while warning against measures hindering competition. CEO Brian Armstrong noted regulation shouldn’t come at the expense of stifling financial system innovation potential. Coinbase’s position makes sense – they want clear rules but not ones that crush their business model or lock out competitors.

The Digital Chamber of Commerce announced a Washington DC summit for March 20, bringing together lawmakers, industry experts, and regulators to discuss CLARITY Act implications. Chamber president Perianne Boring said the event would create open dialogue and collaboration opportunities, hoping to bridge policy and innovation gaps.

The Financial Services Committee scheduled a special session for later this month with industry player testimonies. Chair Maxine Waters indicated the session would gather diverse perspectives to ensure final legislation considers all digital asset ecosystem stakeholders’ needs. Whether that actually happens remains to be seen, but at least they’re talking about it.

Post Views: 15

Bitcoin liquidity is quietly tightening as exchange balances sink to levels not seen since November 2017, signaling a shrinking pool of readily tradable supply just as market demand cycles intensify.

The State Street Technology Select Sector SPDR ETF (XLK 0.75%) and the iShares U.S. Technology ETF (IYW 0.95%) both aim to capture the performance of the U.S. technology sector, appealing to investors seeking growth through leading tech companies.

This comparison examines their costs, risk profiles, and portfolio makeup to help clarify which fund may appeal to different investors.

Snapshot (cost & size)MetricXLKIYWIssuerSPDRiSharesExpense ratio0.08%0.38%1-yr return (as of March 15, 2026)27.89%28.22%Dividend yield0.56%0.15%Beta (5Y monthly)1.241.28AUM$87.7 billion$19.4 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months.

XLK is more affordable than IYW, with a significantly lower expense ratio. XLK also offers a higher dividend yield, which could appeal to investors seeking long-term passive dividend income.

Performance & risk comparisonMetricXLKIYWMax drawdown (5 y)-33.56%-39.44%Growth of $1,000 over 5 years$2,082$2,163What's insideIYW tracks the U.S. technology sector, holding 140 stocks. Its sector allocation is 89% technology, with small allocations to communication services, industrials, and consumer cyclical, and its top holdings include Nvidia, Apple, and Microsoft. The fund was launched 25 years ago, offering investors a long track record and broad diversification within tech and related segments.

By contrast, XLK is focused almost exclusively on technology stocks. It holds just 71 positions, with 99% of assets devoted to tech. Its top three holdings match IYW’s, and having launched around 28 years ago, it offers a similarly long history.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsBoth XLK and IYW provide access to leading U.S. technology companies, but their difference in diversification is an important factor for investors to consider.

IYW holds roughly twice as many stocks as XLK, but it leans more heavily on its top holdings. While both funds share the same top three stocks, those positions make up 44.43% of IYW’s portfolio compared to 37.91% for XLK.

This means that while IYW provides exposure to a broader swath of the tech sector and related industries, it’s more concentrated on mega-cap tech giants. If Nvidia, Apple, and Microsoft significantly under- or overperform, it will likely affect IYW more than XLK.

Case in point: IYW has experienced a steeper five-year drawdown, but it’s also slightly outperformed XLK in one- and five-year total returns.

Fees and income are other factors to consider with these two funds. XLK has an edge on both fronts, with a lower expense ratio and higher dividend yield. Investors can expect to pay $8 per year in fees for every $10,000 invested in XLK, compared to $38 per year for every $10,000 in IYW. While it’s a marginal difference on the surface, it can add up for long-term investors.

Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Microsoft, and Nvidia and is short shares of Apple. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026.

SO WHAT: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Boston Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=55398 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific's U.S. Electrophysiology segment; notably, that management was aware that the segment's growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to defendants' statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Boston Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=55398 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288614

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaudited financial results for the fourth quarter and full year of 2025.

Fourth Quarter 2025 Financial and Operating Highlights:

Revenue reached US$85.2 million, representing 43.0% year-over-year growth, meeting the upper end of our guidance range. Gross margin achieved a company-record level of 40.4%, an impressive expansion of 3.6 percentage points and 2.2 percentage points compared with same period of 2024 and third quarter of 2025. The strong gross margin, driven by our product mix, more than offset the headwinds from foreign currency fluctuations, memory chip cost increases and tariffs amid macroeconomic uncertainties. GAAP and adjusted net loss[1] was US$11.0 million and US$6.4 million, narrowing by 70.2% and 71.6% compared with the fourth quarter of 2024. As of December 31, 2025, cash and cash equivalents and restricted cash was US$112.9 million, compared with US$102.6 million of cash balance as of September 30, 2025 and US$110.7 million as of December 31, 2024. The cash balance increase was driven primarily by strong operating performance and tight working capital management. Despite strategic risk purchases of key components for the future, our inventory balance decreased to US$72.8 million compared with US$87.7 million as of September 30, 2025. This reflects ongoing improvements in inventory management. For the first quarter of 2026, management currently expects net revenues to be between US$50.0 million and US$55.0 million, which would represent a year-over-year increase of approximately 30% to 43%. New product debut:
-  Amazfit Active Max: Positioned as a premium all–round smartwatch, it delivers long battery life, large display, and advanced health and fitness tracking for daily and structured training use.
-  Amazfit T–Rex Ultra 2: As an ultra–rugged outdoor flagship watch, it features military–grade durability, professional positioning, and robust performance for extreme outdoor environments.
-  Amazfit Active 3 Premium: Designed for new and entry-level runners, it offers structured guidance with built-in running workouts, Zepp Coach™ Training Plans, advanced running metrics, and long battery life to help users build strength, consistency, and confidence for long-term progress toward personal milestones. Further expansion of our Amazfit Athletes team: We are pleased to announce the expansion of HYROX athlete roster, including the return of Hunter McIntyre (USA) for another season. And welcome Amanal Petros, Germany's fastest marathon runner and one of Europe's leading long-distance athletes, as well as Josh Kerr, a two-time Olympic Medalist and World Champion middle-distance runner, to our growing athletes' family. Full Year 2025 Financial and Operating Highlights:

Revenue reached US$258.9 million, representing 41.8% year-over-year growth compared with US$182.6 million in the full year of 2024. Gross margin in the full year 2025 was 38.3%. We remain on track with our margin-expansion strategy initiated in the second half of 2023 and expect the trend to continue into 2026 as we further optimize our product mix and supply chain efficiency. GAAP and adjusted net loss was US$40.1 million and US$31.5 million, compared with GAAP and adjusted net loss of US$75.7 million and US$56.7 million in 2024. GAAP and adjusted operating loss[2] as percentage of sales was 11.3% and 9.4% in 2025, representing significant improvement compared with 25.9% and 22.0% in 2024. As of December 31, 2025, cash and cash equivalents and restricted cash was US$112.9 million, compared with US$110.7 million of cash balance as of December 31, 2024. "2025 marked a pivotal year for Zepp Health as our branded products delivered over 50% year-over-year revenue growth and recorded margin expansion," commented Wayne Huang, Founder, Chairman and CEO of Zepp Health.

"These results reflect the success of our multi-year transformation as we evolve from a volume-driven wearable brand into a premium-focused global brand built around Hybrid Training. Through our expanding product portfolio—from the $169 Active series to the $550 T-Rex Ultra flagship—together with growing pricing power and deeper engagement with performance communities such as HYROX, Amazfit is increasingly becoming part of how athletes train, compete, and share their performance."

Mr. Leon Deng, Zepp's Chief Financial Officer, added, "In the fourth quarter of 2025, we delivered robust revenue growth, with total revenue reaching US$85.2 million, a 43.0% increase compared to the fourth quarter of 2024. This performance was driven by strong sales of our Amazfit-branded products during the Black Friday and Christmas sales seasons. We are confident in our ability to maintain this growth momentum into 2026.

Our gross margin for the fourth quarter reached a record high of 40.4%, a significant 3.6% improvement compared to the fourth quarter of 2024 and a 2.2% increase over the third quarter of 2025. This exceptional margin expansion was driven by a more favourable product mix and our ability to sustain pricing power during promotional periods. We remain on track with the margin enhancement efforts that began in late 2023, and we expect this trend to continue into the new year as we optimize our product mix and improve supply chain efficiencies.

Total GAAP operating expenses for the quarter amounted to US$38.3 million, while adjusted operating expenses[3] were US$37.1 million, adjusted operating expenses as a percentage of sales improved by 5.7%, compared to the fourth quarter of 2024. Although we experienced an increase in operating expenses due to strategic investments in brand and marketing activities, the majority of this increase was attributable to US$5.2 million specially identified provisions for sales channel optimization and brand and intellectual property protection. We expect these costs to normalize in 2026.

Thanks to strong revenue growth, improved gross margins, and effective cost control, our adjusted operating loss for the fourth quarter was significantly reduced to US$2.7 million, compared with US$7.4 million in the fourth quarter of 2024.

As of December 31, 2025, we ended the quarter with US$112.9 million in cash and cash equivalents, compared with US$102.6 million as of September 30, 2025 and US$110.7 million as of December 31, 2024. The cash balance increase was driven primarily by strong operating performance and tight working capital management. Our inventory balance stood at US$72.8 million, a reduction from US$87.7 million as of September 30, 2025, reflecting our ongoing improvements in inventory management and preparation for upcoming product launches. Since the beginning of 2023, we have proactively reduced our short and long-term debt, lowering our total loan balance by US$58.2 million. We remain focused on optimizing our capital structure going forward. Moreover, our share repurchase program will proceed in 2026, underscoring our confidence in Zepp Health's long-term growth and our commitment to delivering shareholder value.

For the first quarter of 2026, we expect revenue in the range of US$50.0 million to US$55.0 million, representing an increase of 30% to 43% year-over-year. This forecast reflects our strong execution, resilient operations, and continued profitability improvement as we enter the next phase of Zepp Health's growth journey."

[1] Adjusted net income/(loss) attributable to Zepp Health Corporation represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release.

[2] Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release.

[3] Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Please refer to the section titled "Reconciliation of GAAP and non-GAAP results"

Fourth Quarter of 2025 Financial Results

Revenues

Revenues for the fourth quarter of 2025 reached US$85.2 million, an increase by 43.0% and 12.4% from the fourth quarter of 2024 and the third quarter of 2025, respectively. The year-over-year sales increase was driven by growth of all the product lines, including sports, balance and youth lines. The quarter-over-quarter sales growth was mainly driven by the Black Friday and Christmas sales season, as well as the new product launches.

Gross Margin

Gross margin in the fourth quarter of 2025 was 40.4%, compared to 36.8% in the fourth quarter of 2024. The company-record high gross margin was primarily driven by favourable product mix and higher portion of new product sales. The shift away from lower-margin legacy products toward newer, higher-value SKUs naturally elevated our margin profile. At the same time, we maintained price integrity even during highly promotional periods like Black Friday, further boosting margins. The strong gross margin, driven by our product mix, more than offset the headwinds from foreign exchange fluctuations, memory chip cost increases and tariffs amid macroeconomic uncertainties.

Research and Development Expenses

Research and development expenses in the fourth quarter of 2025 were US$11.0 million, which remained relatively stable compared with US$11.1 million and US$10.8 million in the same period of 2024 and third quarter of 2025.We continued to invest in a series of cutting-edge products as well as new technologies, including AI, to maintain our competitive edge against our peers. At the same time, we focused on refined research and development approaches, consistently evaluating resource efficiency to optimize return on investment and productivity.

Selling and Marketing Expenses

Selling and marketing expenses in the fourth quarter of 2025 were US$15.9 million, compared with US$13.3 million and US$12.0 million in the same period of 2024 and the third quarter of 2025. Out of the year over year increase of US$2.6 million, US$1.0 million is directly attributable to certain e-commerce platform charges, which was a kind of fixed-ratio sale channel charges, to drive revenue growth, the remaining US$1.6 million was primarily due to frontloaded investments in marketing and branding activities that fuelled the adoption of new products including Active Max and T-Rex 3 Pro. We continued to invest in selling and marketing activities and expand our Amazfit Athletes team to build brand recognition. At the same time, we consistently pushed on retail profitability and channel mix improvement, including through meticulous refinement of our retail channels and strategic staffing arrangements across sales regions.

General and Administrative Expenses

General and administrative expenses were US$11.4 million in the fourth quarter of 2025, compared with US$6.6 million and US$7.0 million in the same period of 2024 and the third quarter of 2025. The year over year increase is due to US$4.7 million specially identified provision as a result of the termination old business model and sales channel, and another US$0.5 million related to certain brand and IP protection activities. We continued to streamline overhead, maintaining disciplined cost control while improving operating efficiency.

Operating Expenses

Total operating expenses for the fourth quarter of 2025 were US$38.3 million, compared with US$30.9 million and US$29.8 million in the same period of 2024 and the third quarter of 2025. The increase is directly attributable to certain US$1.0 million e-commerce platform charges to drive revenue growth, and US$1.6 million frontloaded of some marketing and branding investments that fuelled the adoption of new products, as well as US$4.7 million specially identified provision for optimizing sales channels and business models, along with US$0.5 million expenditures for brand and intellectual property protections. We will maintain our cost-conscious approach and remain committed to investing in R&D and marketing activities to ensure our long-term competitiveness. 

Operating Income/(Loss)

GAAP and adjusted operating results were loss of US$3.9 million and US$2.7 million, compared with loss of US$8.9 million and US$7.4 million in the fourth quarter of 2024. The operating losses included US$4.7 million specially identified provision for bad debt and business model optimization, and US$0.8 million patent fee and branding protection expenditure, both are occasionally not happening regularly.

Net Income/(Loss)

Net loss attributable to Zepp Health Corporation for the fourth quarter of 2025 was US$11.0 million, compared to net loss of US$36.9 million in the fourth quarter of 2024. The net loss for the fourth quarter of 2025 included operating loss of US$3.9 million, among which US$5.5 million was specially identified provisions for sales channel optimization and brand and intellectual property protection, as well as income tax impacts of US$2.1 million (primarily resulting from valuation allowance for deferred tax assets) and net investment results of US$3.5 million (including impairment loss from investments, loss from equity method investments, and loss from fair value change of long-term investment), both of which are non-cash in nature. Adjusted net loss attributable to Zepp Health Corporation was US$6.4 million, compared to adjusted net loss of US$22.5 million in the fourth quarter of 2024.  

Liquidity and Capital Resources

As of December 31, 2025, the Company had cash balance (including restricted cash) increased sequentially, and end of balance as of US$112.9 million, compared with US$102.6 million of cash balance as of September 30, 2025. This cash position provides ample runway for the Company to invest and seize potential market opportunities.

The Company recorded inventory of US$72.8 million as of December 31, 2025, which was lower than US$87.7 million as of September 30, 2025. We will continue to manage the inventory level tightly. The Company improved its management of accounts receivable collections and accounts payable payment terms. The Company will continue to manage working capital closely.

Long-term and short-term debt levels increased as of December 31, 2025 compared with September 30, 2025 due to timing differences. We manage the overall debt levels to remain stable and optimize debt structure, capitalizing on favourable rates to minimize interest payments. We will take on some debt depends on one quarter and retire some in the other. Since the beginning of 2023, the Company has cumulatively retired US$58.2 million of debt, and will continue to optimize the capital structure for the Company.

Share Repurchase Program Update

The Company announced in its third quarter 2021 earnings release that the board had authorized a share repurchase program of up to US$20 million through November 2022. On November 21, 2022, the board authorized a 12-month extension of the Company's share repurchase program. On November 20, 2023, the board further authorized the Company to extend its share repurchase program for another 12 months. On November 18, 2024, the board further authorized the Company to extend its share repurchase program for another 24 months. Pursuant to the extended share repurchase program, the Company may repurchase its shares in the form of ADSs and/or ordinary shares through November 2026 with an aggregate value equal to the remaining balance under the share repurchase program. As of December 31, 2025, the Company had used US$16.2 million to repurchase approximately 2.2 million ADSs. The Company expects to fund the repurchases under the extended share repurchase program out of its existing cash balance.

Full Year 2025

Revenues

Total revenues of 2025 reached US$258.9 million, an increase of 41.8% from the full year of 2024. In 2025, Amazfit-branded products accounted for 100% of our total revenues, compared with 94.0% in 2024. Sales of our Amazfit-branded product increased by 50.9% as compared with 2024. The year over year sales increase was driven by growth of all the product lines, including sports, balance and youth lines.

Gross Margin

Gross margin in the full year 2025 was 38.3%, compared with 38.5% in the full year of 2024. We remain on track with our margin-expansion strategy initiated in the second half of 2023 and expect the trend to continue into 2026 as we further optimize our product mix and supply chain efficiency. 

Research and Development Expenses

Research and development expenses for the full year 2025 were US$45.3 million, decreased by 1.8% compared to full year of 2024. We continued to invest in a series of cutting-edge products set to launch as well as new technologies, including AI, to maintain our competitive edge against our peers. At the same time, we focused on refined research and development approaches, consistently evaluating resource efficiency to optimize return on investment and productivity.

Selling and Marketing Expenses

Selling and marketing expenses for the full year 2025 were US$53.8 million, an increase of 15.8% year-over-year. Out of the year over year increase of US$7.4 million, US$2.6 million is directly attributable to certain e-commerce platform charges to drive revenue growth, the remaining US$4.8 million was primarily due to frontloaded some investments in marketing and branding activities that fuelled the adoption of new products. At the same time, we consistently pushed on retail profitability and channel mix improvement, which included meticulous refinement of our retail channels and strategic staffing arrangements across sales regions. We are committed to investing efficiently in marketing and branding to ensure our sustainable growth. 

General and Administrative Expenses

General and administrative expenses were US$29.3 million in the full year 2025, an increase from US$24.9 million in the full year of 2024.The year over year increase is due to US$5.7 million specially identified provision as a result of the termination old business model and sales channel and US$1.2 million expense related to certain brand and IP protection activities. Excluding those, general and administrative expenses decreased compared with full year of 2024. We continued to streamline overhead, maintaining disciplined cost control while improving operating efficiency. 

Operating Expenses

Total operating expenses for the full year 2025 were US$128.4 million, an increase of 9.3% year-over-year. Adjusted operating expenses, were US$123.6 million, compared with US$110.4 million for the full year 2024. The increase is directly attributable to certain e-commerce platform charges to drive revenue growth, and frontloading of some marketing and branding investments that fuelled the adoption of new products, as well as certain specially identified provisions. The aggregate impact associated with those items is US$14.3 million. We will maintain our cost-conscious approach and remain committed to investing in R&D and marketing activities to ensure our long-term competitiveness.

Net Income/(Loss)

Net loss attributable to Zepp Health Corporation for the full year of 2025 was US$40.1 million, compared with US$75.7 million in net loss in 2024. The net loss for the full year of 2025 included operating loss of US$29.2 million, among which US$7.2 million was specially identified provisions for sales channel optimization and brand and intellectual property protection, as well as income tax impacts of US$2.5 million (primarily resulting from valuation allowance for deferred tax assets) and net investment results of US$4.2 million (including impairment loss from investments, loss from equity method investments, and gain from fair value change of long-term investment), both of which are non-cash in nature. Adjusted net loss attributable to Zepp Health Corporation was US$31.5 million, compared to adjusted net loss of US$56.7 million in the fourth quarter of 2024.

Outlook

The first quarter is typically a seasonally low quarter for our industry. For the first quarter of 2026, the Company's management currently expects net revenues to be between US$50.0 million and US$55.0 million, which would represent an increase of approximately 30% to 43% from US$38.5 million in the first quarter of 2025.

This outlook is based on current market conditions and reflects the Company's current and preliminary estimates of market, operating conditions and customer demand, which are all subject to change.

Conference Call

The Company's management team will hold a conference call at 9:30 p.m. Eastern Time on Sunday, March 15, 2026 to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

US (Toll Free):

+1-888-346-8982

International:

+1-412-902-4272

Mainland China (Toll Free):

400-120-1203

Hong Kong (Toll Free):

800-905-945

Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation".

Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.

A telephone replay will be available one hour after the call until March 22, 2026 by dialing:

US Toll Free:

+1-855-669-9658

International:

+1-412-317-0088

Replay Passcode:

8917498

About Zepp Health Corporation

Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across globe, especially in Europe and USA regions.

Use of Non-GAAP Measures

We use adjusted net income/(loss), a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Adjusted EBIT represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/expense, and (vii) interest income and interest expense. Adjusted net income/(loss) attributable to Zepp Health Corporation is a non-GAAP measure, which excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted net income/(loss) per share and per ADS attributable to Zepp Health Corporation.

We believe that adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income/(loss) and net income/(loss) attributable to Zepp Health Corporation. We believe adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

Adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income/(loss), basic and diluted net income/(loss) per share and per ADS attributable to Zepp Health Corporation or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted EBIT and adjusted net income/(loss) attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the recognition of the Company's Amazfit-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions around the globe. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact: 

In China:
Zepp Health Corporation
Grace Yujia Zhang
Email: [email protected]

Piacente Financial Communications
Tel: +86-10-6508-0677
Email: [email protected]

Zepp Health Corporation

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

As of December 31,

As of December 31,

2024

2025

US$

US$

Assets

Current assets:

Cash and cash equivalents

91,069

57,046

Restricted cash

19,666

55,887

Accounts receivable, net

62,965

66,908

Amounts due from related parties

2,663

6,665

Inventories, net

56,789

72,756

Short-term investments

997

-

Prepaid expenses and other current assets

17,415

34,263

Total current assets

251,564

293,525

Property, plant and equipment, net

6,898

5,662

Intangible asset, net

7,091

13,611

Goodwill

9,581

9,581

Long-term investments

225,910

220,047

Deferred tax assets

17,465

15,743

Amount due from related parties, non-current

2,019

991

Other non-current assets

4,607

3,718

Operating lease right-of-use assets

3,458

1,958

Total assets

528,593

564,836

Zepp Health Corporation

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

As of December 31, 

As of December 31,

2024

2025

US$

US$

Liabilities

Current liabilities:

Accounts payable

51,077

80,768

Advance from customers

197

76

Amount due to related parties

2,477

654

Accrued expenses and other current liabilities

37,576

37,527

Income tax payables

508

366

Notes payable

61,679

111,725

Short-term bank borrowings

41,853

55,728

Total current liabilities

195,367

286,844

Deferred tax liabilities

3,117

2,673

Long-term borrowings

75,241

59,475

Other non-current liabilities

133

209

Non-current operating lease liabilities

2,007

1,102

Total liabilities

275,865

350,303

Zepp Health Corporation

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

As of December 31,

As of December 31,

2024

2025

US$

US$

Equity

Ordinary shares

26

26

Additional paid-in capital

278,116

281,990

Treasury stock

(14,993)

(16,153)

Accumulated retained earnings/(loss)

28,618

(11,450)

Accumulated other comprehensive loss

(40,178)

(39,880)

Total Zepp Health Corporation shareholders' equity

251,589

214,533

Noncontrolling interest

1,139

-

Total equity

252,728

214,533

Total liabilities and equity

528,593

564,836

Zepp Health Corporation

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

For the Three Months Ended December 31,

2024

2025

US$

US$

Revenues

59,542

85,165

Cost of revenues

(37,613)

(50,750)

Gross profit

21,929

34,415

Operating expenses:

Selling and marketing

(13,251)

(15,929)

General and administrative

(6,555)

(11,375)

Research and development

(11,061)

(10,982)

Total operating expenses

(30,867)

(38,286)

Operating loss

(8,938)

(3,871)

Other income and expenses:

Interest income

771

322

Interest expense

(1,447)

(1,616)

Gain/(Loss) from fair value change of long-term investments

33

(358)

Impairment loss from investments

(10,129)

(2,194)

Other expense, net

(767)

(222)

Loss before income tax and loss from equity method investments

(20,477)

(7,939)

Income tax expenses

(13,574)

(2,068)

Loss before loss from equity method investments

(34,051)

(10,007)

Net loss from equity method investments

(2,850)

(964)

Net loss

(36,901)

(10,971)

Less: Net loss attributable to noncontrolling interest

(25)

-

Net loss attributable to Zepp Health Corporation

(36,876)

(10,971)

Basic and diluted net loss per share attributable to Zepp Health

Corporation 

(0.14)

(0.04)

Basic and diluted net loss per ADS (16 ordinary shares equal to 1

ADS) 

(2.29)

(0.69)

Weighted average number of shares used in computing basic and

diluted net loss per share

257,216,039

254,033,558

Zepp Health Corporation

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

For the Three Months Ended December 31,

2024

2025

US$

US$

Total operating expenses

(30,867)

(38,286)

Share-based compensation expenses

951

656

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

567

483

Total adjusted operating expenses

(29,349)

(37,147)

Operating loss

(8,938)

(3,871)

Share-based compensation expenses

951

656

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

567

483

Adjusted operating loss

(7,420)

(2,732)

Net loss

(36,901)

(10,971)

Share-based compensation expenses

951

656

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

567

483

Interest income

(771)

(322)

Interest expense

1,447

1,616

(Gain)/Loss from fair value change of long-term investments

(33)

358

Impairment loss from investments

10,129

2,194

Income tax expenses

13,574

2,068

Loss from equity method investments

2,850

964

Adjusted EBIT[4]

(8,187)

(2,954)

Net loss attributable to Zepp Health Corporation

(36,876)

(10,971)

Share-based compensation expenses

951

656

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

567

483

Gain from fair value change of long-term investments

(33)

358

Impairment loss from investments

10,129

2,194

Tax effects on non-GAAP adjustments

(91)

(82)

Loss from equity method investments

2,850

964

Adjusted net loss attributable to Zepp Health Corporation

(22,503)

(6,398)

Adjusted basic and diluted net loss per share attributable

to Zepp Health Corporation[5]

(0.09)

(0.03)

Adjusted basic and diluted net loss per ADS (16 ordinary

shares equal to 1 ADS) 

(1.40)

(0.40)

Weighted average number of shares used in computing

adjusted basic and diluted net loss per share

257,216,039

254,033,558

Share-based compensation expenses included are follows:

Selling and marketing

94

356

General and administrative

433

28

Research and development

424

272

Total

951

656

[4] Adjusted EBIT is a non-GAAP financial measure, which is defined as net loss, excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/ expense, and (vii) interest income and interest expense.

[5] Adjusted diluted net income/(loss) is the abbreviation of adjusted net (loss)/income attributable to Zepp Health Corporation, which is a non-GAAP measure and excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted basic and diluted net loss per ADS attributable to Zepp Health Corporation.

Zepp Health Corporation

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

Years Ended December 31,

2024

2025

US$

US$

Revenues

182,603

258,897

Cost of revenues

(112,369)

(159,707)

Gross profit

70,234

99,190

Operating expenses:

Selling and marketing

(46,471)

(53,829)

General and administrative

(24,854)

(29,273)

Research and development

(46,159)

(45,318)

Total operating expenses

(117,484)

(128,420)

Operating loss

(47,250)

(29,230)

Other income and expenses:

Interest income

3,672

1,526

Interest expense

(5,552)

(5,697)

Gain from fair value change of long-term investments

2,011

76

Impairment loss from investments

(10,129)

(2,194)

Other(expense) /income, net

(656)

56

Loss before income tax and loss from equity method investments

(57,904)

(35,463)

Income tax expenses

(13,693)

(2,537)

Loss before loss from equity method investments

(71,597)

(38,000)

Net loss from equity method investments

(4,211)

(2,068)

Net loss

(75,808)

(40,068)

Less: Net loss attributable to noncontrolling interest

(75)

-

Net loss attributable to Zepp Health Corporation

(75,733)

(40,068)

Basic and diluted net loss per share attributable to Zepp Health

Corporation 

(0.29)

(0.16)

Basic and diluted net loss per ADS (16 ordinary shares equal to 1

ADS) 

(4.68)

(2.52)

Weighted average number of shares used in computing basic and

diluted net loss per share

258,876,120

254,431,492

Zepp Health Corporation

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands of U.S. dollars ("US$")

except for number of shares and per share data, or otherwise noted)

Years Ended December 31,

2024

2025

US$

US$

Total operating expenses

(117,484)

(128,420)

Share-based compensation expenses

4,778

2,492

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

2,267

2,310

Total adjusted operating expenses

(110,439)

(123,618)

Operating loss

(47,250)

(29,230)

Share-based compensation expenses

4,778

2,492

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

2,267

2,310

Adjusted operating loss

(40,205)

(24,428)

Net loss

(75,808)

(40,068)

Share-based compensation expenses

4,778

2,492

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

2,267

2,310

Interest income

(3,672)

(1,526)

Interest expense

5,552

5,697

Gain from fair value change of long-term investments

(2,011)

(76)

Impairment loss from investments

10,129

2,194

Income tax expenses

13,693

2,537

Loss from equity method investments

4,211

2,068

Adjusted EBIT

(40,861)

(24,372)

Net loss attributable to Zepp Health Corporation

(75,733)

(40,068)

Share-based compensation expenses

4,778

2,492

Amortization of intangible assets resulting from acquisitions

and business cooperation agreements

2,267

2,310

Gain from fair value change of long-term investments

(2,011)

(76)

Impairment loss from investments

10,129

2,194

Tax effects on non-GAAP adjustments

(365)

(383)

Loss from equity method investments

4,211

2,068

Adjusted net loss attributable to Zepp Health Corporation

(56,724)

(31,463)

Adjusted basic and diluted net loss per share attributable

to Zepp Health Corporation

(0.22)

(0.12)

Adjusted basic and diluted net loss per ADS (16 ordinary

shares equal to 1 ADS) 

(3.51)

(1.97)

Weighted average number of shares used in computing

adjusted basic and diluted net loss per share

258,876,120

254,431,492

Share-based compensation expenses included are follows:

Selling and marketing

462

487

General and administrative

2,245

1,132

Research and development

2,071

873

Total

4,778

2,492

SOURCE Zepp Health Corp.

1.1K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

1.96K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, March 15, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Camping World Holdings, Inc. (NYSE: CWH) between April 29, 2025 and February 24, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026.

SO WHAT: If you purchased Camping World securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Camping World class action, go to https://rosenlegal.com/submit-form/?case_id=55841 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Camping World Holdings’ business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) Camping World overstated its ability to “surgically manage [its] inventory” to optimize profit using “data analytics;” (2) Camping World overstated the retail demand of consumers it was experiencing and/or reasonably expected; (3) as a result, Camping World would require “strict, corrective inventory management objectives,” negatively impacting gross profit and margins; (4) Camping World’s inadequate systems and processes prevented it from ensuring reasonably accurate disclosures and/or guidance, including about the health of its balance sheet and/or the ability to manage Selling, General & Administrative (“SG&A”) expenses; and (5) as a result of the foregoing, defendants’ positive statements about Camping World’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Camping World class action, go to https://rosenlegal.com/submit-form/?case_id=55841 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, March 15, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Tennant Company has suffered a 21.6% share price decline due to weak Q4 2025 results, primarily from ERP rollout issues and volume drops. Despite recent pain, TNC's fundamentals and 2026 guidance support maintaining a 'buy' rating, with expectations of revenue and profit recovery. Management projects 2026 revenue of $1.24–$1.28B, EBITDA of $175–$190M, and adjusted EPS of $4.70–$5.30, with organic sales growth of 3–6.5%.

On February 17, 2026, Parkman Healthcare Partners disclosed a new position in EyePoint (EYPT 6.20%), acquiring 1,088,033 shares in the fourth quarter.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Parkman Healthcare Partners established a new stake in EyePoint by purchasing 1,088,033 shares during the fourth quarter. The quarter-end value of the position increased by $19.88 million as a result of the acquisition.

What else to knowThis was a new position; EyePoint represented 1.89% of Parkman’s 13F reportable AUM as of December 31, 2025.Top holdings after the filing:NYSE: BSX: $47.73 million (4.5% of AUM)NASDAQ: PODD: $40.04 million (3.8% of AUM)NASDAQ: DXCM: $38.99 million (3.7% of AUM)NYSE: SYK: $37.07 million (3.5% of AUM)NYSE: CVS: $35.73 million (3.4% of AUM)As of Friday, EyePoint shares were priced at $13.20, up a staggering 93% over the past year and well outperforming the S&P 500’s roughly 20% gain in the same period.Company overviewMetricValuePrice (as of Friday)$13.20Market capitalization$1.1 billionRevenue (TTM)$31.37 millionNet income (TTM)($231.96 million)Company snapshotEyePoint Pharmaceuticals develops and commercializes ophthalmic products, including ILUVIEN, YUTIQ, DEXYCU, and pipeline assets such as EYP-1901 for retinal diseases.The company generates revenue primarily through product sales and strategic collaborations focused on sustained-release drug delivery for eye disease treatment.Its main customers are healthcare providers and ophthalmologists treating patients with diabetic macular edema, uveitis, and other retinal conditions in the United States, China, and the United Kingdom.EyePoint Pharmaceuticals is a biotechnology company specializing in innovative sustained-release drug delivery systems for ocular diseases. The company leverages proprietary technologies and strategic alliances to address unmet needs in ophthalmology, with a focus on chronic and severe retinal conditions. Its differentiated product pipeline and commercial partnerships support its positioning as a leader in ophthalmic therapeutics.

What this transaction means for investorsBreakthrough medicines often create enormous value long before they ever reach pharmacy shelves. Investors who specialize in healthcare know that the real opportunity frequently emerges when a company is approaching pivotal clinical data, not after approval. That is the backdrop surrounding today.

Shares of EyePoint are booming as the firm works on advancing DURAVYU, a sustained-release therapy designed to treat serious retinal diseases such as wet age-related macular degeneration and diabetic macular edema. Two Phase 3 trials evaluating the drug in wet AMD have enrolled more than 900 patients, with topline data expected beginning in mid-2026, per the company’s latest quarterly financials. If successful, the therapy could compete in a massive ophthalmology market currently dominated by frequent anti-VEGF injections.

Financially, the company remains firmly in development mode. Full-year revenue totaled about $31 million in 2025, while the company posted a net loss of roughly $232 million as research spending accelerated to support its late-stage trials. Still, EyePoint ended the year with about $306 million in cash and investments, enough to fund operations into late 2027.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Insulet. The Motley Fool recommends CVS Health and DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.

Walmart (WMT +0.95%) is eating Target's (TGT +1.37%) lunch right now. To put a number on that, Walmart's same-store sales rose 4.6% in the most recent quarter while Target's fell 2.5%. Target is attempting to turn its business around by offering lower prices on thousands of products. That should help, but it doesn't necessarily change the bigger problem the company faces.

Consumers are worried and cutting their budgets Target's move to cut prices is a recognition of the market realities it faces. Inflation has pushed prices higher, and consumers are looking to make every dollar count. Economic concerns have pushed consumers into stores known for having low prices. This has been a huge benefit to Walmart, which brands itself as offering low prices.

Image source: Getty Images.

Target's branding is very different. The retailer has positioned itself as more upscale, with stores that offer higher-quality, higher-priced product offerings. It is currently out of step with consumers, and that is clearly showing up in its same-store sales figures. Cutting prices will likely help the company keep loyal customers happy, but it won't likely change Target's image overall.

Target is protecting its brand The truth is that Target doesn't want to materially change its industry position. It has carefully honed its image for decades, differentiating itself from Walmart, its biggest rival. To suddenly shift to an everyday-low-price model would destroy years of effort. If management did make a decision like that, investors would be justifiably concerned about the business's future.

Today's Change

(

1.37

%) $

1.59

Current Price

$

117.34

Which is why it is important to note that Target is also planning to invest in store remodeling and staffing, to help elevate the shopping experience at its stores. Those moves should also help Target retain customers while also supporting the company's core branding. The real story here is that economic worries mean that Target has to walk a tightrope. Cutting costs and maintaining its branding are both necessary in the face of the market uncertainty it is currently facing.

When times improve, Target's customers will likely return The goal is really to muddle through this difficult period until consumers feel more confident again. Target doesn't want to lose more customers, so it is cutting costs where it can. However, it is also investing to ensure that it maintains the higher-end shopping experience it has long offered, so customers will trade up again when times are better. In the end, inflation is a real problem, but the company's brand positioning is the complicating factor that investors need to watch right now.

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026.

SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Nektar class action, go to https://rosenlegal.com/submit-form/?case_id=55599 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Nektar class action, go to https://rosenlegal.com/submit-form/?case_id=55599 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288563

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

On February 17, 2026, Solas Capital Management disclosed a new position in Euronet Worldwide (EEFT 1.79%), acquiring 73,494 shares in the fourth quarter. The shares were worth $5.59 million at quarter’s end.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Solas Capital Management established a new stake in Euronet Worldwide, acquiring 73,494 shares. The quarter-end value of the position stood at $5.59 million.

What else to knowThis was a new position in Euronet Worldwide, representing 3.17% of Solas Capital Management, LLC’s 13F reportable AUM after the filing.Top holdings after the filing included:NASDAQ: FENC: $19.72 million (11.2% of AUM)NASDAQ: EPSN: $16.45 million (9.3% of AUM)NYSE: SNDA: $14.86 million (8.4% of AUM)NASDAQ: ACOG: $12.79 million (7.3% of AUM)NYSE: MOH: $11.86 million (6.7% of AUM)As of Friday, shares of Euronet Worldwide were priced at $71.13, down 30% over the prior year and vastly underperforming the S&P 500’s roughly 20% gain in the same period.Company overviewMetricValueMarket capitalization$3 billionRevenue (TTM)$4.24 billionNet income (TTM)$309.5 millionPrice (as of Friday)$71.13Company snapshotEuronet Worldwide delivers payment and transaction processing solutions, including ATM and POS services, prepaid mobile airtime, electronic payment products, and global money transfer services.The company generates revenue primarily through transaction fees from its ATM/POS network, prepaid product distribution, and money transfer operations across a global footprint.Its main customers include financial institutions, retailers, merchants, agents, and individual consumers seeking electronic payment and money transfer solutions.Euronet Worldwide operates a large-scale payments infrastructure, managing tens of thousands of ATMs and extensive POS and money transfer networks worldwide. The company leverages its technology-driven platform to serve diverse clients in the financial services and retail sectors, emphasizing secure, efficient, and accessible electronic transactions. Its global reach and multi-segment business model provide competitive advantages in the fast-evolving payments industry.

What this transaction means for investorsSharp sell-offs in profitable fintech infrastructure companies can create unusual opportunities for patient investors, and that may be the lens through which this latest investment should be viewed.

Euronet operates a global payments backbone that quietly powers millions of transactions across ATMs, point-of-sale networks, prepaid platforms, and cross-border remittances. The company finished 2025 with more than 56,000 installed ATMs and an enormous money transfer and payments network spanning more than 200 countries.

Despite that scale, the stock has struggled over the past year, even as the underlying business continues to grow. Revenue rose to about $4.24 billion in 2025, up roughly 6% year over year, while net income ticked up to approximately $309 million. Adjusted earnings per share reached $9.61, reflecting 12% growth from the prior year.

With management expecting adjusted earnings to grow another 10% to 15% in 2026 as digital money transfer, merchant acquiring, and international payments expansion gain traction, it seems clear why a fund like Solas might choose to step in now.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Euronet Worldwide. The Motley Fool has a disclosure policy.

On February 17, 2026, Solas Capital Management disclosed a new position in Primo Brands Corporation (PRMB 0.43%), acquiring 460,619 shares in the fourth quarter.

What happenedSolas Capital Management disclosed in a Securities and Exchange Commission (SEC) filing dated February 17, 2026, that it acquired 460,619 shares of Primo Brands Corporation in the fourth quarter. The fund’s quarter-end position in PRMB was valued at $7.53 million, marking the establishment of this new stake.

What else to knowThis was a new position for Solas Capital Management, LLC; PRMB represented 4.27% of 13F reportable AUM after the trade.Top holdings after the filing:NASDAQ: FENC: $19.72 million (11.2% of AUM)NASDAQ: EPSN: $16.45 million (9.3% of AUM)NYSE: SNDA: $14.86 million (8.4% of AUM)NASDAQ: ACOG: $12.79 million (7.3% of AUM)NYSE: MOH: $11.86 million (6.7% of AUM)As of Friday, shares of PRMB were priced at $20.76, down 33.5% over the past year and well underperforming the S&P 500’s roughly 20% gain in the same period.Company overviewMetricValuePrice (as of Friday)$20.76Market capitalization$7.6 billionRevenue (TTM)$6.66 billionNet income (TTM)($60.1 million)Company snapshotPrimo Brands Corporation offers bottled water, purified and spring water, sparkling and flavored water, mineral water, water dispensers, filtration equipment, and coffee under multiple regional and international brands.The firm operates a direct-to-consumer and business delivery model, generating revenue primarily through recurring water sales, equipment rentals, and related services in North America and Europe.It serves residential consumers, small and medium-sized businesses, as well as regional and national corporate clients and retailers.Primo Brands Corporation is a leading provider of bottled water and water filtration solutions, with a diversified product portfolio and a broad geographic footprint. The company leverages a network of established brands and direct distribution to drive recurring revenue streams. Its focus on both consumer and commercial markets positions it to capture demand for safe, high-quality hydration solutions.

What this transaction means for investorsPrimo Brands has been reshaping itself recently, and the latest earnings suggest the integration strategy is starting to pay off. Net sales jumped 29% to about $6.7 billion in 2025, while adjusted EBITDA climbed to roughly $1.45 billion as margins improved and scale efficiencies began to show. Fourth-quarter sales alone reached about $1.55 billion, rising more than 11% year over year, alongside a sharp increase in adjusted earnings.

The stock has responded accordingly, rising roughly 27% over the past year with much of the momentum coming after the earnings report highlighted stronger operating trends. That makes this move from Solas pretty notable because that gain has been captured since it made its hefty investment. Within the broader portfolio, the position stands out as a consumer staples play among a collection of healthcare and biotech holdings that dominate top positions. Ultimately, for long-term investors, the real question is whether Primo’s national distribution network and recurring delivery model can continue translating scale into durable profitability as demand for bottled and purified water keeps expanding.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Primo Brands. The Motley Fool has a disclosure policy.

Candelo Capital Management disclosed a new position in Granite Construction (GVA 2.38%) on February 17, 2026, acquiring 49,088 shares in an estimated $5.66 million trade based on quarterly average pricing.

What happenedAccording to a February 17, 2026, SEC filing, Candelo Capital Management LP established a new position in Granite Construction by purchasing 49,088 shares. The reported quarter-end value of the stake totaled $5.66 million, with the increase reflecting the addition of new shares and changes in the company’s stock price over the period.

What else to knowThis is a new position for the fund, now representing 5.05% of Candelo’s 13F reportable assets under management.Top five holdings after the filing:NYSE:ATI: $7.28 million (6.6% of AUM)NYSE:TDY: $6.74 million (6.2% of AUM)NYSE:UNP: $5.75 million (5.2% of AUM)NYSE:GVA: $5.66 million (5.1% of AUM)NASDAQ:MKSI: $5.61 million (5.1% of AUM)As of Friday, Granite Construction shares were priced at $120.73, up 67% over the past year and well outperforming the S&P 500’s roughly 20% gain in the same period.Company overviewMetricValuePrice (as of Friday)$120.73Market capitalization$5.3 billionRevenue (TTM)$4.42 billionNet income (TTM)$193.00 millionCompany snapshotGranite Construction delivers heavy civil infrastructure construction and produces construction materials such as aggregates and asphalt.The firm generates revenue through large-scale public and private construction projects, as well as the sale of construction materials to internal and external customers.It serves federal, state, and local government agencies, transportation authorities, utilities, developers, and industrial clients across the United States.Granite Construction is a leading U.S. infrastructure contractor with a diversified portfolio spanning transportation, water, and complex site development projects. The company leverages nearly a century of operational experience to execute projects for both public and private sector clients, supported by integrated materials production capabilities.

What this transaction means for investorsGrantice just delivered a record year operationally. Revenue climbed to roughly $4.4 billion in 2025, up about 10% year over year, while net income attributable to shareholders surged to about $193 million, up over 60% from the prior year. Meanwhile, adjusted EBITDA jumped 30% to roughly $527 million, reflecting improved margins and stronger project execution across its construction and materials businesses.

Perhaps more important for long-term investors is the visibility Granite now has into future growth. The company ended the year with nearly $7 billion in committed and awarded projects, a record pipeline that management says should support continued revenue expansion as public infrastructure spending remains strong.

The stock’s performance reflects that momentum. Shares have climbed about 67% over the past year and are up roughly 5% so far in 2026, even as the broader market has slipped about 3%. All of this to say that with this underlying momentum, it’s not hard to see why a fund like Candelo would be stepping in to buy shares.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teledyne Technologies. The Motley Fool recommends Union Pacific. The Motley Fool has a disclosure policy.

Oil prices extended gains on Monday as the U.S.-Israeli war against Iran entered a third week, ‌putting oil infrastructure at risk and keeping the Strait of Hormuz shut in the biggest disruption to global supplies ever.

Oil futures rose in early trade on supply disruption concerns.

Gold fell in early trade as rising energy prices spurred by the Middle East conflict exacerbate inflation worries.

Meta is reportedly planning layoffs that could impact at least 20% of its workforce.

That’s according to a report Friday (March 13) from Reuters, which noted that the cuts come as the tech giant looks to offset its heavy spending on artificial intelligence infrastructure, while also preparing for what it hopes will be more efficiency from AI-assisted workers.

The company has not set a date for the job cuts and the scope of the layoffs is still not final, the report added, citing sources familiar with the matter. These sources, who spoke anonymously as they were not permitted to share the information, said that top executives at Meta had recently shared the plans with managers and told them to start figuring out how to cut back.

“This is speculative reporting about theoretical approaches,” Meta spokesperson Andy Stone told Reuters in response to queries about the plan.

The report noted that if Meta does let go of 20% of its workforce, it will mark the largest round of layoffs since the company’s “year of efficiency” cuts in 2022 and 2023. The company had nearly 79,000 workers at the end of 2025, per its most recent filing.

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Meta laid off 11,000 staffers in November 2022, or around 13% of its workforce, before cutting another 10,000 jobs a few months later.

Advertisement: Scroll to Continue

As Reuters pointed out, Meta CEO Mark Zuckerberg has over the past year pushed the company to compete more forcefully in the AI space, offering massive compensation packages to attract leading AI researchers.

The company has been making some acquisitions in the AI space. These include its planned purchase of Chinese startup Manus and, as of last week, Moltbook, a social networking platform for AI agents.

The company also plans to spend between $115 billion and $135 billion this year as it races to construct “data centers, chips and infrastructure capable of supporting increasingly powerful AI models,” as PYMNTS wrote last week.

This is a level of spending that puts Meta in the company of some of the biggest investors in AI infrastructure, including Amazon, Google and Microsoft.

“The difference is that those companies operate cloud businesses that directly monetize the computing power they build,” the report added. “Training models for internal use is only one part of the equation. The same infrastructure can also be rented to thousands of enterprise customers. Meta does not have that outlet.”

For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.